"FDA Proposes Removing Ineffective Decongestant from Cold Medicines"

The FDA has proposed removing oral phenylephrine from over-the-counter cold medications due to its ineffectiveness as a nasal decongestant. This decision comes after an FDA review of available data and the conclusion of an advisory committee that the drug does not work.

Why is Oral Phenylephrine Being Removed?

• Ineffectiveness: The FDA has found that oral phenylephrine is not effective in treating nasal congestion. Only a small fraction of the drug is absorbed into the bloodstream when taken orally, making it less effective than when used as a nasal spray[2][3].

Impact on Cold Medications

• Wide Use: Oral phenylephrine is commonly found in cold medicines like DayQuil, Theraflu, and Sudafed.
• Alternative Options: Patients can still use other over-the-counter medications like pseudoephedrine (available for adults 18+ without a prescription) or phenylephrine nasal sprays, which are effective because they directly reach the nasal passages[2][3].

Public Comment Period

• The proposal is open for public comment until May 7, 2025. After the comment period, the FDA will make a final decision. Companies can continue to market these products during this time, but they must reformulate or remove them if the ingredient is eventually banned[2][4].

Context and Background

• The FDA has conducted a comprehensive review of the data supporting oral phenylephrine’s effectiveness, including past studies and newer clinical data. An advisory committee previously voted against continued use of the ingredient based on its ineffectiveness[3][4].

By removing oral phenylephrine from over-the-counter cold medications, the FDA aims to ensure that drugs are both safe and effective. This decision does not reflect on the safety of the drug but rather its lack of effectiveness as a nasal decongestant.